Company news
Anavex Life Sciences Corp. (NASDAQ:AVXL) news
Every Anavex Life Sciences Corp. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Anavex Life Sciences: Fiscal Q3 Earnings Snapshot
August 25, 2026
Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update
August 25, 2026
Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees
August 17, 2026
Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders
August 11, 2026
Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
August 3, 2026
Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update
July 30, 2026
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
May 22, 2026
Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim C...
May 6, 2026
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease
April 14, 2026
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
April 7, 2026
Anavex Life Sciences Provides Comprehensive Regulatory Update
March 30, 2026
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation ...
March 23, 2026
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease
March 20, 2026
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease ...
March 17, 2026
Anavex Life Sciences to Present at the Citizens Life Sciences Conference
March 3, 2026
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
February 25, 2026
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
February 23, 2026
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
February 9, 2026
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
February 3, 2026
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of ...
January 13, 2026
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
January 8, 2026
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
January 6, 2026
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
December 18, 2025
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
December 12, 2025
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 26, 2025
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
November 25, 2025
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
November 19, 2025
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
November 18, 2025
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease
November 14, 2025
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease...
October 29, 2025
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of De...
October 10, 2025
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
October 2, 2025
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program
October 2, 2025
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III ...
September 30, 2025
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinic...
September 9, 2025
Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
September 2, 2025
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
August 26, 2025
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheim...
August 20, 2025
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
August 12, 2025
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
August 5, 2025
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Ope...
July 31, 2025
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
May 14, 2025
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
May 13, 2025
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
May 6, 2025
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
May 1, 2025
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference
April 30, 2025
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
April 23, 2025
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East
April 21, 2025
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Al...
April 5, 2025
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025